The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy
Cardiac hypertrophy is broadly defined as an increase in heart mass. Heart enlargement in a setting of cardiac disease is referred to as pathological hypertrophy and often progresses to heart failure. Physiological hypertrophy refers to heart growth in response to postnatal development, exercise tra...
Saved in:
Published in | Future medicinal chemistry Vol. 6; no. 2; p. 205 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
01.02.2014
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Cardiac hypertrophy is broadly defined as an increase in heart mass. Heart enlargement in a setting of cardiac disease is referred to as pathological hypertrophy and often progresses to heart failure. Physiological hypertrophy refers to heart growth in response to postnatal development, exercise training and pregnancy, and is an adaptive response associated with the activation of cardioprotective signaling cascades. miRNAs have emerged as novel therapeutic targets for numerous pathologies, and miRNA-based therapies have already entered clinical trials. The identification of miRNAs differentially regulated during physiological growth may open up new therapeutic approaches for heart failure. In this review, we present information on miRNAs regulated in models of physiological hypertrophy, describe preclinical cardiac disease studies that have successfully targeted miRNAs regulated in settings of physiological growth (miR-34, miR-15, miR-199b, miR-208a and miR-378), and discuss challenges to overcome for the safe entry of miRNA-based therapies into the clinic for heart failure patients. |
---|---|
AbstractList | Cardiac hypertrophy is broadly defined as an increase in heart mass. Heart enlargement in a setting of cardiac disease is referred to as pathological hypertrophy and often progresses to heart failure. Physiological hypertrophy refers to heart growth in response to postnatal development, exercise training and pregnancy, and is an adaptive response associated with the activation of cardioprotective signaling cascades. miRNAs have emerged as novel therapeutic targets for numerous pathologies, and miRNA-based therapies have already entered clinical trials. The identification of miRNAs differentially regulated during physiological growth may open up new therapeutic approaches for heart failure. In this review, we present information on miRNAs regulated in models of physiological hypertrophy, describe preclinical cardiac disease studies that have successfully targeted miRNAs regulated in settings of physiological growth (miR-34, miR-15, miR-199b, miR-208a and miR-378), and discuss challenges to overcome for the safe entry of miRNA-based therapies into the clinic for heart failure patients. |
Author | Bernardo, Bianca C Ooi, Jenny Y Y McMullen, Julie R |
Author_xml | – sequence: 1 givenname: Jenny Y Y surname: Ooi fullname: Ooi, Jenny Y Y organization: Baker IDI Heart & Diabetes Institute, PO Box 6429, St Kilda Road Central, Melbourne 8008, Australia – sequence: 2 givenname: Bianca C surname: Bernardo fullname: Bernardo, Bianca C – sequence: 3 givenname: Julie R surname: McMullen fullname: McMullen, Julie R |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24467244$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8tKAzEYhYMoVms3PoDkBaZObpPMshRvUBSkbi3pnz-dyNxI0kXf3hH1LM5ZfJwD55qc90OPhNyycimZUve-gyUTS1ZXZ-SKaVUVpuZ6RhYpfZWTBDd1pS7JjEtZ6cmuyOe2QZobjHbEYw5AxyFjn4Nt6eBpF95fV4lGPBxbm9HR0NOEOYf-kH742JxSGNrhEGAqgI0uWKDNacSY4zDRG3LhbZtw8Zdz8vH4sF0_F5u3p5f1alOAUCIXQgpjmFFOO80dlEJZY8FLw8qKGe8N-hJkyRUTwGuLYGrQwKVG59leIJ-Tu9_d8bjv0O3GGDobT7v_o_wbYGlWsA |
CitedBy_id | crossref_primary_10_1016_j_lfs_2019_116748 crossref_primary_10_3390_ijms22052299 crossref_primary_10_3892_etm_2020_8517 crossref_primary_10_1080_15476286_2016_1181251 crossref_primary_10_1016_j_mce_2018_05_004 crossref_primary_10_1007_s40139_019_00191_9 crossref_primary_10_1152_ajpheart_00899_2014 crossref_primary_10_1101_cshperspect_a029827 crossref_primary_10_1007_s12551_018_0439_y crossref_primary_10_1186_s43044_019_0003_5 crossref_primary_10_1016_j_micpath_2021_105361 crossref_primary_10_3389_fphys_2021_650566 crossref_primary_10_1016_j_ccl_2016_06_002 crossref_primary_10_3892_mmr_2019_10519 crossref_primary_10_1016_j_jacbts_2020_03_006 crossref_primary_10_1038_s41371_018_0097_3 crossref_primary_10_1111_jcmm_12733 crossref_primary_10_1113_JP271161 crossref_primary_10_4081_ejh_2022_3426 crossref_primary_10_1080_21655979_2021_1964892 crossref_primary_10_1016_j_jshs_2018_09_008 crossref_primary_10_1016_j_bbrc_2019_10_038 crossref_primary_10_3389_fphar_2018_01090 crossref_primary_10_1186_s12920_021_01036_4 crossref_primary_10_1152_japplphysiol_00904_2018 crossref_primary_10_1038_nrendo_2016_76 crossref_primary_10_3389_fphys_2020_565307 crossref_primary_10_1136_bmjopen_2022_068600 crossref_primary_10_1016_j_exger_2018_06_023 crossref_primary_10_34172_bi_2020_32 crossref_primary_10_1016_j_ebiom_2019_07_051 crossref_primary_10_1536_ihj_16_020 crossref_primary_10_1042_CS20220391 crossref_primary_10_1093_ilar_ilw028 crossref_primary_10_1111_1440_1681_12281 crossref_primary_10_1016_j_prp_2018_09_004 crossref_primary_10_1113_JP270685 crossref_primary_10_3390_cells3030778 crossref_primary_10_1080_14728222_2016_1212017 crossref_primary_10_1096_fj_14_253856 crossref_primary_10_1007_s00109_019_01790_0 crossref_primary_10_1152_physrev_00043_2016 crossref_primary_10_1007_s10495_024_01954_5 crossref_primary_10_3389_fcvm_2023_1250029 crossref_primary_10_1007_s00204_015_1477_x crossref_primary_10_4155_fmc_15_107 crossref_primary_10_3389_fvets_2021_652224 crossref_primary_10_1016_j_gene_2018_01_047 crossref_primary_10_1113_JP272512 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.4155/fmc.13.196 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1756-8927 |
ExternalDocumentID | 24467244 |
Genre | Research Support, Non-U.S. Gov't Journal Article Review |
GroupedDBID | --- 0R~ 1LI 4.4 53G 7X7 8FE 8FH 8FI 8FJ ABJNI ABUWG ACFQB ACGFS ACWKX AENEX AFFYO AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI BPHCQ BVXVI CCPQU CGR CUY CVF EBS ECM EIF EJD F5P FYUFA H13 HCIFZ HMCUK HZ~ LK8 M4Z M7P NPM O9- OVD PQQKQ RPM TDBHL TEORI TFL TMEDX TVSSL UKHRP |
ID | FETCH-LOGICAL-c353t-34388185d7d72dc035a8acf4810618ff8ef0c402513c29aec89c7c247edf1b3e2 |
IngestDate | Sat Sep 28 07:59:16 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c353t-34388185d7d72dc035a8acf4810618ff8ef0c402513c29aec89c7c247edf1b3e2 |
PMID | 24467244 |
ParticipantIDs | pubmed_primary_24467244 |
PublicationCentury | 2000 |
PublicationDate | 2014-02-01 |
PublicationDateYYYYMMDD | 2014-02-01 |
PublicationDate_xml | – month: 02 year: 2014 text: 2014-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Future medicinal chemistry |
PublicationTitleAlternate | Future Med Chem |
PublicationYear | 2014 |
SSID | ssj0000328965 |
Score | 2.3054607 |
SecondaryResourceType | review_article |
Snippet | Cardiac hypertrophy is broadly defined as an increase in heart mass. Heart enlargement in a setting of cardiac disease is referred to as pathological... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 205 |
SubjectTerms | Animals Cardiomegaly - metabolism Cardiomegaly - physiopathology Cardiomegaly - therapy Female Heart - growth & development Heart - physiology Hepatitis C - therapy MicroRNAs - antagonists & inhibitors MicroRNAs - metabolism MicroRNAs - therapeutic use Physical Conditioning, Animal Pregnancy Signal Transduction |
Title | The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24467244 |
Volume | 6 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZaeuGCCi3QB8gH1EuaJYnjxHtsEahC2lVVbaVyoXLGtthDk9U2l-XXM7bjJC0PAZdolcmuIs-345nxzDeEvMNdLVVJCrFSoGOMN7JYJkzHmssKKjBSuFT2bF5cXOefb_jNcBTjukvaagLff9lX8j9axXuoV9sl-w-a7X8Ub-Bn1C9eUcN4_WsdjxqoolXT2uIf71_eLa_mZ_ZQwA2b15ZjKbrXrszZlW-4nEZv-sAhBaJvGJeu23UTWKzDBE9HPRJO4u3zYVBcn6VtlqFaZhN9iXoP-dwmHNfKZWTPXQZlSMzOYGbZv-vQqK278sUuC5HmoXDZbiLecpa8iMXUN_oH01qMEJSNzaRrtf7JfFvnxq05TFI2Sf2o25EeV3dOkeiRFGXmaSP_LH1EpR1E22S7FHbOx7xL7bhtm2HsWXBPYWvf5P3wHpYyuvvuo_DDuSGLXfKsix_omQfDc7Kl6xfk5NITkG9O6WKAw_0pPaGXAzX5Zo98RTEdIYb2iKGNoR4xtEcMXdY0IMbKHyCGdoihI8Tsk-tPHxcfLuJuwkYMjLM2ZjkT1mNTpSozBQnjUkgwubCJAmGM0CaB3IahDLKp1CCmUEKWl1qZtGI6e0me1E2tXxPKtTR5IpRIQObAEskhKyqG8fqUATP8gLzy63a78jQqt2FFD38rOSJPB6wdkx2D_1v9Bp3AtnrrlPcD5r9hoQ |
link.rule.ids | 780 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+therapeutic+potential+of+miRNAs+regulated+in+settings+of+physiological+cardiac+hypertrophy&rft.jtitle=Future+medicinal+chemistry&rft.au=Ooi%2C+Jenny+Y+Y&rft.au=Bernardo%2C+Bianca+C&rft.au=McMullen%2C+Julie+R&rft.date=2014-02-01&rft.eissn=1756-8927&rft.volume=6&rft.issue=2&rft.spage=205&rft_id=info:doi/10.4155%2Ffmc.13.196&rft_id=info%3Apmid%2F24467244&rft_id=info%3Apmid%2F24467244&rft.externalDocID=24467244 |